<DOC>
	<DOCNO>NCT00229684</DOCNO>
	<brief_summary>This prospective 24-week , randomize , parallel-group , multi-center , active-controlled ( pioglitazone 45 mg ) open-label study design assess effect tesaglitazar 2 mg per day component renal excretion creatinine type 2 diabetic . The study comprise 2-week enrollment period , follow 24-week double blind treatment period 8-week follow-up period</brief_summary>
	<brief_title>ARMOR ( Analyzing Renal Mechanisms Creatinine Excretion Patients On tesaglitazaR )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Provision write informed consent Men woman &gt; =45 year age Female patient : postmenopausal , hysterectomized , childbearing potential , use reliable method birth control Diagnosed type 2 diabetes Treated diet alone treatment single oral antidiabetic agent low dos two oral antidiabetic agent Type 1 diabetes New York Heart Association heart failure Class III IV Treatment chronic insulin History hypersensitivity intolerance peroxisome proliferatoractivated receptor agonist ( like Actos Avandia ) , fenofibrate , metformin 3hydroxy3methylglutaryl coenzyme A reductase inhibitor ( statin ) History druginduced myopathy druginduced creatine kinase elevation , liver enzyme elevation , neutropenia ( low white blood cell ) Creatinine level twice normal range Creatine kinase 3 time upper limit normal Received investigational product clinical study within 12 week Any clinically significant abnormality identify physical examination , laboratory test electrocardiogram , judgment investigator would compromise patient 's safety successful participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Type 2 Diabetes</keyword>
</DOC>